Skip to content
  • ENGLISHENGLISH
  • 繁體中文繁體中文
回首頁回首頁回首頁
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Event
    • Knowledge
  • Investors
    • Shareholder Services
    • Financials
    • Corporate Governance
  • Contact Us
MENU Close

MEDIA

  • News
  • Event
  • Knowledge
Menu
  • News
  • Event
  • Knowledge
Media releases

2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6

Comments Off on 2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6
13 . 5 . 2022
Media releases

2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN.

Comments Off on 2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN.
13 . 5 . 2022
Media releases

2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642

Comments Off on 2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642
9 . 5 . 2022
Media releases

2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q.

Comments Off on 2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q.
21 . 4 . 2022
Media releases

2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000

Single-ascending-dose (SAD) study successfully demonstrated the safety, tolerability, and sustained release profile at least 3 months resulting from ALA-1000 injection in patients with opioid dependence.

Comments Off on 2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
14 . 1 . 2022
Media releases

2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139..

Comments Off on 2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139..
17 . 12 . 2021
  • 1
  • 2
  • 3
  • 4
  • Go to the next page
回首頁

ABOUT

  • Company Profile
  • Leadership Team
  • History&Milestones
Menu
  • Company Profile
  • Leadership Team
  • History&Milestones

PRODUCTS

  • Products Pipeline
  • Contract Manufacturing
Menu
  • Products Pipeline
  • Contract Manufacturing

media

  • News
  • Event
  • Knowledge
Menu
  • News
  • Event
  • Knowledge

investors

  • Shareholder Services
  • Financials
  • Corporate Governance
Menu
  • Shareholder Services
  • Financials
  • Corporate Governance

CONTACT us

  • Contact Us
Menu
  • Contact Us
Share on linkedin
  • Contact Us
  • Privacy Policy
Copyright © - 2022 Alar Pharmaceuticals Inc . All right reserved.
Close
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Event
    • Knowledge
  • Investors
    • Shareholder
    • Financials
    • Corporate Governance
  • Contact Us
    • Contact Us
×

Cart